Year None2022202120202019201820172016201520142013 Mar 26 View HTML version View PDF Version Late-breaking Phase 3 Data at AAD 2022 Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Prurigo Nodularis Mar 15 View HTML version View PDF Version Students Win $1.8 Million at Regeneron Science Talent Search 2022 for Exceptional Research on Neutron Star--Black Hole Systems, Narrowband Radar, and Ribosome Movement in Protein Translation Feb 28 View HTML version View PDF Version Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein Feb 26 View HTML version View PDF Version Late-breaking Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Improved Signs and Symptoms of Eosinophilic Esophagitis Feb 26 View HTML version View PDF Version Late-breaking Phase 3 Data at 2022 AAAAI Annual Meeting Show Dupixent® (dupilumab) Significantly Reduced Itch and Hives in Patients with Chronic Spontaneous Urticaria Feb 18 View HTML version View PDF Version Regeneron and Sanofi Provide Update on Ongoing Dupixent® (dupilumab) Chronic Spontaneous Urticaria Phase 3 Program Feb 17 View HTML version View PDF Version Regeneron Announces Investor Conference Presentations Feb 11 View HTML version View PDF Version Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting Feb 10 View HTML version View PDF Version FDA Accepts Dupixent® (dupilumab) for Priority Review in Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Feb 4 View HTML version View PDF Version Regeneron Reports Fourth Quarter and Full Year 2021 Financial and Operating Results First page « Previous page ‹ Page 1 Current page 2 Page 3 Next page › Last page »